Tango Therapeutics Inc
NASDAQ:TNGX

Watchlist Manager
Tango Therapeutics Inc Logo
Tango Therapeutics Inc
NASDAQ:TNGX
Watchlist
Price: 3.91 USD 7.71% Market Closed
Market Cap: 420m USD
Have any thoughts about
Tango Therapeutics Inc?
Write Note

Intrinsic Value

TNGX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one TNGX stock under the Base Case scenario is 3.58 USD. Compared to the current market price of 3.91 USD, Tango Therapeutics Inc is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TNGX Intrinsic Value
3.58 USD
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Tango Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TNGX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TNGX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Tango Therapeutics Inc

Provide an overview of the primary business activities
of Tango Therapeutics Inc.

What unique competitive advantages
does Tango Therapeutics Inc hold over its rivals?

What risks and challenges
does Tango Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Tango Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Tango Therapeutics Inc.

Provide P/S
for Tango Therapeutics Inc.

Provide P/E
for Tango Therapeutics Inc.

Provide P/OCF
for Tango Therapeutics Inc.

Provide P/FCFE
for Tango Therapeutics Inc.

Provide P/B
for Tango Therapeutics Inc.

Provide EV/S
for Tango Therapeutics Inc.

Provide EV/GP
for Tango Therapeutics Inc.

Provide EV/EBITDA
for Tango Therapeutics Inc.

Provide EV/EBIT
for Tango Therapeutics Inc.

Provide EV/OCF
for Tango Therapeutics Inc.

Provide EV/FCFF
for Tango Therapeutics Inc.

Provide EV/IC
for Tango Therapeutics Inc.

Show me price targets
for Tango Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Tango Therapeutics Inc?

How accurate were the past Revenue estimates
for Tango Therapeutics Inc?

What are the Net Income projections
for Tango Therapeutics Inc?

How accurate were the past Net Income estimates
for Tango Therapeutics Inc?

What are the EPS projections
for Tango Therapeutics Inc?

How accurate were the past EPS estimates
for Tango Therapeutics Inc?

What are the EBIT projections
for Tango Therapeutics Inc?

How accurate were the past EBIT estimates
for Tango Therapeutics Inc?

Compare the revenue forecasts
for Tango Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Tango Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Tango Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Tango Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Tango Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Tango Therapeutics Inc with its peers.

Analyze the financial leverage
of Tango Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Tango Therapeutics Inc.

Provide ROE
for Tango Therapeutics Inc.

Provide ROA
for Tango Therapeutics Inc.

Provide ROIC
for Tango Therapeutics Inc.

Provide ROCE
for Tango Therapeutics Inc.

Provide Gross Margin
for Tango Therapeutics Inc.

Provide Operating Margin
for Tango Therapeutics Inc.

Provide Net Margin
for Tango Therapeutics Inc.

Provide FCF Margin
for Tango Therapeutics Inc.

Show all solvency ratios
for Tango Therapeutics Inc.

Provide D/E Ratio
for Tango Therapeutics Inc.

Provide D/A Ratio
for Tango Therapeutics Inc.

Provide Interest Coverage Ratio
for Tango Therapeutics Inc.

Provide Altman Z-Score Ratio
for Tango Therapeutics Inc.

Provide Quick Ratio
for Tango Therapeutics Inc.

Provide Current Ratio
for Tango Therapeutics Inc.

Provide Cash Ratio
for Tango Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Tango Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Tango Therapeutics Inc?

What is the current Free Cash Flow
of Tango Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Tango Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Tango Therapeutics Inc

Current Assets 300.8m
Cash & Short-Term Investments 293.3m
Other Current Assets 7.5m
Non-Current Assets 51.6m
PP&E 49m
Other Non-Current Assets 2.6m
Current Liabilities 37.6m
Accounts Payable 4.1m
Accrued Liabilities 17.9m
Other Current Liabilities 15.6m
Non-Current Liabilities 85.7m
Other Non-Current Liabilities 85.7m
Efficiency

Earnings Waterfall
Tango Therapeutics Inc

Revenue
43.4m USD
Operating Expenses
-183.1m USD
Operating Income
-139.7m USD
Other Expenses
16.3m USD
Net Income
-123.4m USD

Free Cash Flow Analysis
Tango Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TNGX Profitability Score
Profitability Due Diligence

Tango Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
Negative Revenue Growth Forecast
Declining ROE
16/100
Profitability
Score

Tango Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

TNGX Solvency Score
Solvency Due Diligence

Tango Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
61/100
Solvency
Score

Tango Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TNGX Price Targets Summary
Tango Therapeutics Inc

Wall Street analysts forecast TNGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TNGX is 11.73 USD with a low forecast of 8.08 USD and a high forecast of 16.8 USD.

Lowest
Price Target
8.08 USD
107% Upside
Average
Price Target
11.73 USD
200% Upside
Highest
Price Target
16.8 USD
330% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TNGX?

Click here to dive deeper.

Dividends

Tango Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TNGX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TNGX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Tango Therapeutics Inc Logo
Tango Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

420m USD

Dividend Yield

0%

Description

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 91 full-time employees. The company went IPO on 2020-09-03. The firm is engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). Its TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. The MTAP-deletion occurs in all human tumors, including cancers with unmet need, such as squamous cell lung, esophageal and bladder cancer. The Company’s USP1, is a synthetic lethal that target for BRCA1-mutant breast, ovarian and prostate cancer. The USP1 treats a patient population for poly (ADP-ribose) polymerase (PARP) inhibitors that are operative against cancers with BRCA1 and BRCA2 mutations.

Contact

MASSACHUSETTS
Cambridge
100 Binney St, Suite 700
+18573204900.0
www.tangotx.com

IPO

2020-09-03

Employees

91

Officers

President, CEO & Director
Dr. Barbara L. Weber M.D.
President of Research & Development
Dr. Adam S. Crystal M.D., Ph.D.
Founder
Dr. Timothy K. Lu M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Antoni Ribas M.D., Ph.D.
Chief Financial Officer
Mr. Timothy Redfern
Head of Technical Operations
Dr. Michael Palmieri Ph.D.
Show More
Chief Scientific Officer
Mr. Jannik N. Andersen Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TNGX stock?

The intrinsic value of one TNGX stock under the Base Case scenario is 3.58 USD.

Is TNGX stock undervalued or overvalued?

Compared to the current market price of 3.91 USD, Tango Therapeutics Inc is Overvalued by 9%.

Back to Top